Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
(NASDAQ:SLDB), – Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation – CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received […]